Home > Back to Publisher > Report Information

Immunotherapy of Cancer

BCC Research
March 30, 2007
192 Pages - SKU: WA1484490

Abstract Table of Contents Related Reports

This report contains: Analyses of products and applications in the cancer immunotherapy sector, including biological response modifiers (cytokines), monoclonal antibody-based products, therapeutic vaccines and other cancer immunotherapies; An overview of the global market, including historical data for cancer treatment and therapies, the latest market trends, and 5-year forecasts and estimates through 2012; A section on industry structure with strategies employed by Big Pharma as well as top-selling drug patent expirations and how this relates to the overall pharmaceutical industry and biotechnology companies in particular; Sections on products and applications with synopses of more than 100 cancer immunotherapy drug and vaccine products, including those currently marketed and those in Phase III or later development; Analyses of patents within the past few decades; Profiles for important businesses.

INTRODUCTION: CONTRIBUTION OF THE STUDY AND FOR WHOM; OBJECTIVES AND GOALS OF THE STUDY; STUDY SCOPE AND FORMAT; METHODOLOGY; INFORMATION SOURCES; AUTHOR’S CREDENTIALS; RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE; BY OTHER AUTHORS; BCC ONLINE SERVICES; DISCLAIMER
EXECUTIVE SUMMARY: SUMMARY TABLE GLOBAL MARKET FORECAST FOR; IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS); SUMMARY FIGURE GLOBAL MARKET FORECAST FOR; IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)
OVERVIEW: DEFINITION AND ETIOLOGY OF Cancer; CANCER STATISTICS
TABLE 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)
TABLE 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006
TABLE 3 CANCER PREVALENCE RATES IN THE U.S., 2003*
TABLE 3 (CONTINUED): IMMUNOTHERAPY OF CANCER; TYPES OF CANCER FOR WHICH IMMUNOTHERAPY; TREATMENTS EXIST OR ARE LIKELY TO BE INTRODUCED BY 2012; BREAST CANCER; COLORECTAL CANCER; HEAD AND NECK CANCER; KIDNEY CANCER; LEUKEMIAS; Leukemias (Continued); LIVER CANCER; LUNG CANCER; MALIGNANT MELANOMA; MULTIPLE MYELOMA; NONHODGKIN’S LYMPHOMA; OSTEOSARCOMA; OVARIAN CANCER; PANCREATIC CANCER; PROSTATE CANCER; STOMACH CANCER; CURRENT METHODS OF TREATMENT; SURGERY; RADIATION THERAPY; PHARMACEUTICAL THERAPY; IMMUNOTHERAPY; INFLAMMATORY RESPONSE; Cell-Mediated Immunity; Humoral Immunity; Macrophage Processing; Nonspecific Immunity; CYTOKINES; Two Types of Cytokines; MONOCYTES; PHAGOCYTES; SPECIFIC IMMUNITY; Lymphocytes; B-Cells; T-Cells; NK Cells; CLINICAL APPROACHES TO IMMUNOTHERAPY; Passive Cellular Immunotherapy; Dealing with Significant Toxicity; Passive Humoral Immunotherapy; Active Specific Immunotherapy; Nonspecific Immunotherapy; TYPES OF IMMUNOTHERAPY PRODUCTS; Biological Response Modifiers
TABLE 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 6 (CONTINUED)
TABLE 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS: Colony Stimulating Factors; Treating Neutropenic Fevers; A Justified Expense; Interferons; A Family of Small Proteins; Anticancer Effects; Side Effects; Production of Interferon; Interferon-alpha; Interferon-beta; Interferon-Beta-1a; Interleukins; Interleukin-2; Other Infection-Fighting Cells; Side Effects; Tumor Necrosis Factor; ANTIBODIES; ANTIBODY FORMS IN PRODUCTS; Abtides; Antibody Conjugates; Antiserums; Bispecific Antibodies; Camouflaged Antibodies; Chimeric Antibodies; Humanized Antibodies; Fully Human Antibodies; Progenitor Stem Cells; Single-Chain Antibodies; Synthetic Antibodies; VACCINES; ANTIGENS: THEIR ROLE IN CANCER VACCINES; VACCINE DEVELOPMENT STRATEGIES; A SUMMARY OF TWO APPROACHES: LOW-TECH VS. HIGHTECH; TECHNOLOGY ADVANCES; PRODUCTS AND APPLICATIONS; IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
TABLE 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006: MECHANISM OF ACTION OF SELECTED IMMUNOTHERAPY PRODUCTS
TABLE 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS: BIOLOGICAL RESPONSE MODIFIERS; THE MARKET FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER
TABLE 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS): COLONY STIMULATING FACTORS; MARKETED BRM PRODUCTS FOR THE TREATMENT OF CANCER
TABLE 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER: Aranesp; Granocyte; Leukine; Neorecormon; Neulasta/Neupopeg/Neupogen/Granulokine; Neumega; Procrit; Stemgen; The Market for Colony Stimulating Factors
TABLE 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENT BY PRODUCT, THROUGH 2012 ($ MILLIONS): The Market for Colony Stimulating Factors to Treat; Cancer
TABLE 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS): Colony Stimulating Factors in Development; INTERFERONS; Interferon-Alpha; Interferon Alpha-2b Products; Marketed Interferon Products for the Treatment of; Cancer
TABLE 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER: Infergen; Intron A and PEG-Intron/Rebetron; PEG-Intron vs. Intron A; Multiferon; Roferon-A; Interferon-Gamma; Actimmune/Imukin; The Market for Interferon Products Used in the; Treatment of Cancer
TABLE 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS): THE MARKET FOR INTERFERONS TO TREAT CANCER
TABLE 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS): INTERLEUKINS; Marketed Interleukin Products for the Treatment of; Cancer
TABLE 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER: ONTAK; PROLEUKIN; The Market for Interleukin Products for the Treatment of; Cancer
TABLE 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS): Product; TUMOR NECROSIS FACTOR INHIBITORS; BIOLOGICAL RESPONSE MODIFIERS IN DEVELOPMENT FOR THE TREAMENT OF CANCER
TABLE 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT: Actimmune; Cintrekedin Besudotox; Multikine; Clinical Trial Results; A Coca-Cola Formula; PEG-Intron; PRX321; Virulizin; COMBINATION CYTOKINE-ANTIBODY TECHNOLOGY IN DEVELOPMENT; MONOCLONAL ANTIBODY PRODUCTS
TABLE 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.
TABLE 20 (CONTINUED): MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER; Avastin; Avastin (Continued); Avastin (Continued); The Avastin Advantage; Medicare Reimbursement Law Supports Use of; Avastin; Bexxar; Bexxar (Continued); Campath/MabCampath; Erbitux
TABLE 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
TABLE 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES: Erbitux (Continued); Herceptin; Mylotarg; Panorex; Rituxan/MabThera; Rituxan/Mabthera (Continued); Vectibix; Zevalin; First Radioimmunotherapeutic Drug; Results of Trials; Sales of Zevalin; THE MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR ALL INDICATIONS; Monoclonal Antibody Sales by Technology
TABLE 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS): Monoclonal Antibody Sales by Target
TABLE 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS): THE MARKET FOR THERAPEUTIC MONOCLONAL; ANTIBODIES TO TREAT CANCER
TABLE 25 GLOBAL MARKET FORECAST FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
TABLE 25 (CONTINUED): THE EUROPEAN MARKET FOR THERAPEUTIC; MONOCLONAL ANTIBODIES
TABLE 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER
TABLE 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
FIGURE 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS): MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT; FOR THE treatment of cancer
TABLE 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 28 (CONTINUED)
TABLE 28 (CONTINUED): Abegrin (formerly Vitaxin); Avastin; Campath/MabCampath; CP-675,206; Denosumab; Herceptin; HuMax-CD4; HuMax-CD20; HuMax-EGFr; MDX-010; Nimotuzumab; OvaRex; Pemtumomab; Rencarex; Rituxan/MabThera; VACCINES
TABLE 29 TUMOR ANTIGENS USED IN CANCER VACCINES: TYPES OF CANCER VACCINES; Whole-cell Vaccines; Antigen/Adjuvant Vaccines; Idiotype Vaccines; Autologous versus Allogenic Vaccines; Dendritic Cell Vaccines; Synthetic Cell Protein Antigens; Gangliosides; Heat Shock Proteins; CANCER VACCINES ON THE WORLDWIDE MARKET; Gardasil; M-Vax; Melacine; OncoVax; THE MARKET FOR CANCER VACCINES
TABLE 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
TABLE 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
FIGURE 6 PERCENTAGE OF GLOBAL MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%): CANCER VACCINES IN DEVELOPMENT
TABLE 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS
TABLE 32 (CONTINUED)
TABLE 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT: Allovectin-7; Allovectin-7 (Continued); BiovaxID; Cervarix; DCVax-Brain; DCVax-Prostate; GMK; GVAX Prostate Vaccine; IGN101; Insegia; Insegia (Continued); Insegia (Continued); M-Vax; Melacine; MyVax Personalized Immunotherapy; Myvax Personalized … (Continued); Oncophage; OncoVax; Panvac-VF; Sipuleucel-T; Stimuvax; TG 4001; TG 1042; Theratope; OTHER IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER; MARKETED PRODUCTS; Gleevec; Iressa; Nexavar; Revlimid; Sprycel; Sutent; Tarceva; Thalomid; Velcade; The Market for Other Immunotherapy Products for the; Treatment of Cancer
TABLE 34 GLOBAL MARKET FORECAST FOR OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS): PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 28 (CONTINUED)
TABLE 28 (CONTINUED): Advexin; BAY 43-9006; Ceplene; Dacogen; Efaproxyn; Genasense; Hycamptin; INGN 241; Junovan; Nexavar; Onconase; Orathecin; Pixantrone; PTK787; Telcyta; Thymitaq; Torisel; Tykerb/Tycerb; Velcade; Zarnestra; Zarnestra (Continued); INDUSTRY; BLOCKBUSTER DRUGS ON THE WORLDWIDE; PHARMACEUTICAL MARKET APPROACH 100; U.S. PHARMACEUTICAL INDUSTRY GROWTH TO INCREASE SLIGHTLY; MORE MERGERS, ACQUISITIONS AND LICENSING; MORE MERGERS, ACQUISITIONS AND … (Continued); BIOGENERICS—THE NEXT REVOLUTION; BIOGENERICS—THE NEXT … (Continued); COMPANY PROFILES; ABGENIX, INC.; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; XenoMouse and XenoMax Technologies; Technology Advantages; Technology Advantages (Continued); CORPORATE STRATEGY; ALFACELL CORPORATION; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY; AMGEN, INC.; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS
TABLE 36 AMGEN’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT: CORPORATE STRATEGY; ANTIGENICS INC; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS
TABLE 37 ANTIGENICS’ PRODUCT PIPELINE: CORPORATE STRATEGY; AVAX TECHNOLOGIES, INC; BUSINESS OVERVIEW; PRODUCTS; CORPORATE STRATEGY; BIOGEN IDEC, INC; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY; BIOMIRA INC; EDMONTON R&D PARK; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY; CHIRON CORPORATION; BUSINESS OVERVIEW; FINANCIAL INFORMATION; LEADING PRODUCTS; CORPORATE STRATEGY; GENENTECH, INC.; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY
TABLE 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
TABLE 38 (CONTINUED)
TABLE 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES: GENMAB A/S; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY; GENZYME CORPORATION; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY; GLAXOSMITHKLINE PLC; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; IMCLONE SYSTEMS, INC; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS
TABLE 40 IMCLONE SYSTEMS’ PRODUCT PIPELINE: CORPORATE STRATEGY; IMMUNOMEDICS, INC; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS
TABLE 41 IMMUNOMEDICS’ THERAPEUTIC PRODUCT PIPELINE
TABLE 41 (CONTINUED): CORPORATE STRATEGY; MEDAREX, INC.; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS
TABLE 42 MEDAREX’S PRODUCT PIPELINE: CORPORATE STRATEGY; MEDIMMUNE, INC.; BUSINESS OVERVIEW; FINANCIAL INFORMATION; LEADING PRODUCTS; Leading Products (Continued)
TABLE 43 MEDIMMUNE’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT: CORPORATE STRATEGY; MERCK & COMPANY, INC; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY; MILLENNIUM PHARMACEUTICALS, INC; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS
TABLE 44 MILLENNIUM’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT: CORPORATE STRATEGY; NORTHWEST BIOTHERAPEUTICS, INC; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS
TABLE 45 NORTHWEST BIOTHERAPEUTICS’ PRODUCT PIPELINE: CORPORATE STRATEGY; PFIZER CORPORATION; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY; Corporate Strategy (Continued); PROGENICS PHARMACEUTICALS, INC.; BUSINESS OVERVIEW; FINANCIAL INFORMATION; LEADING PRODUCTS
TABLE 46 PROGENICS’ PRODUCT PIPELINE: CORPORATE STRATEGY; PROTEIN DESIGN LABS; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS
TABLE 47 PROTEIN DESIGN LABS’ PRODUCTS IN PHASE II OR LATER: CORPORATE STRATEGY; TRANSGENE S/A; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY; VIREXX MEDICAL CORPORATION; BUSINESS OVERVIEW; FINANCIAL INFORMATION; PRODUCTS; CORPORATE STRATEGY
LIST OF TABLES: SUMMARY TABLE GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
TABLE 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)
TABLE 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006
TABLE 3 CANCER PREVALENCE RATES IN THE U.S., 2003*
TABLE 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS
TABLE 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS
TABLE 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006
TABLE 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS
TABLE 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
TABLE 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
TABLE 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENTBY PRODUCT, THROUGH 2012 ($ MILLIONS)
TABLE 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
TABLE 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
TABLE 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)
TABLE 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
TABLE 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER
TABLE 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)
TABLE 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT
TABLE 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.
TABLE 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
TABLE 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
TABLE 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
TABLE 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)
TABLE 25 GLOBAL MARKET FORECAST FOR MONOCLONAL: ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
TABLE 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER
TABLE 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)
TABLE 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 29 TUMOR ANTIGENS USED IN CANCER VACCINES
TABLE 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION
TABLE 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)
TABLE 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS
TABLE 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT
TABLE 34 GLOBAL MARKET FORECAST FOR OTHER CANCER: TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)
TABLE 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER
TABLE 36 AMGEN’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
TABLE 37 ANTIGENICS’ PRODUCT PIPELINE
TABLE 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
TABLE 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
TABLE 40 IMCLONE SYSTEMS’ PRODUCT PIPELINE
TABLE 41 IMMUNOMEDICS’ THERAPEUTIC PRODUCT PIPELINE
TABLE 42 MEDAREX’S PRODUCT PIPELINE
TABLE 43 MEDIMMUNE’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
TABLE 44 MILLENNIUM’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT
TABLE 45 NORTHWEST BIOTHERAPEUTICS’ PRODUCT PIPELINE
TABLE 46 PROGENICS’ PRODUCT PIPELINE
TABLE 47 PROTEIN DESIGN LABS’ PRODUCTS IN PHASE II OR LATER
LIST OF FIGURES: SUMMARY FIGURE GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)
FIGURE 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL: RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)
FIGURE 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)
FIGURE 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)
FIGURE 6 PERCENTAGE OF GLOBAL MARKET HELD BY: AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)

Immunotherapy of Cancer

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service